No Data
No Data
HealthpointCapital and The Orthopaedic Summit: Evolving Techniques Course (OSET) Announce Inaugural Investor Day at Fontainebleau Las Vegas
SAN DIEGO, June 11, 2024 /PRNewswire/ -- HealthpointCapital, the leading private equity firm exclusively focused on the Musculoskeletal Healthcare sector, in partnership with The Orthopaedic Summit:
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that on June 3, 2024, Anika granted: (i)
Stephens & Co. Reiterates Equal-Weight on Anika Therapeutics, Maintains $24 Price Target
Stephens & Co. analyst George Sellers reiterates Anika Therapeutics with a Equal-Weight and maintains $24 price target.
Anika Therapeutics: Caligan Has Agreed to Customary Standstill, Voting Commitments and Other Provisions >ANIK
Anika Therapeutics: Caligan Has Agreed to Customary Standstill, Voting Commitments and Other Provisions >ANIK
Anika Therapeutics: Board Will Temporarily Expand to Ten Directors Until Retirement of Director Jeffery Thompson >ANIK
Anika Therapeutics: Board Will Temporarily Expand to Ten Directors Until Retirement of Director Jeffery Thompson >ANIK
Anika Therapeutics Remains on Track to Generate $25 M-$30 M in Adj EBITDA for 2024
Anika Therapeutics Remains on Track to Generate $25 M-$30 M in Adj EBITDA for 2024